Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
about
Treatment of light chain deposition disease with bortezomib and dexamethasoneCurrent Trends of Renal Impairment in Multiple MyelomaAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Bortezomib in patients with renal impairment.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyPhase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaUpdate on the optimal use of bortezomib in the treatment of multiple myelomaCase report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroidsLate recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case reportBortezomib in the management of multiple myeloma.Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.Proteasome inhibitors in the treatment of multiple myelomaImmunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.The use of novel agents in the treatment of relapsed and refractory multiple myelomaRenal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.Survival from multiple myeloma in England and Wales up to 2001.European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.Bortezomib in the front-line treatment of multiple myeloma.Treatment of relapsed and refractory myeloma.Initial therapy in multiple myeloma: investigating the new treatment paradigm.Kidney disease associated with plasma cell dyscrasiasGuidelines for the diagnosis and management of multiple myeloma 2011.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.Current strategies for treatment of relapsed/refractory multiple myeloma.
P2860
Q24658325-DA92EBEE-9BC2-4E02-9797-D7A136EAE725Q26740444-D7A65048-AE1A-4833-9542-F8DDEA117B8AQ30595175-24A7D7A6-E215-4AA0-A065-39309A7B0CC9Q33376918-37CB01DD-43B1-47F9-879C-BB486DD3C9DDQ33396250-0D57EBCC-9414-4563-967A-3BEADA3A79B3Q33398587-B4938DC3-6D83-45DC-9ABD-2826A94EFF81Q33400871-F6FBEDBB-C6DA-4CC9-8914-22C738A3D684Q33405602-68352915-CF8E-47FE-A22E-536CF83D31EEQ33408056-A4392B00-C592-4194-B392-7BD186EB0559Q33440007-BC46D084-4350-407A-BC3D-653A7005B012Q33874209-39D7632C-D73E-4E0B-A670-2F63A1486AFBQ34096413-AC1E6C9E-93E9-4B69-9BDC-07A7474BC2E3Q34228650-0C506011-7460-4204-9B7B-4C01843D6887Q34418462-9F165F2F-B5AB-463F-94CB-068F756C2494Q34448964-33B2D951-27D7-4247-9406-0E2DCEF2AF48Q34611676-8B03C0D9-DFCD-4887-B581-7DDDF95C2F6BQ34666924-1B969E24-0F9A-408C-93B6-46E002848E84Q35012436-1AFA09B9-5E91-43BF-A4BB-97E9530D351EQ35097319-C11B768D-6FD9-46A9-A415-F30E19B1C1DCQ36209159-8AD04DE5-C657-4EFD-A877-52216D1DABFCQ36686965-B6DC565C-CABC-428C-9A6D-EE4F391C2D86Q36917738-9A25EB61-5D66-4404-A123-9E330B8D46E0Q36930970-467E17CE-A099-4CF2-A587-52F9053603F4Q36934144-D58FE823-ECF7-42D6-9BCD-58F4DC589365Q37112901-B212B6D9-3FBC-4CD5-B76A-60DCA0DD51FDQ37152486-31D21981-25D8-45E8-9C99-2DA80FC95DB0Q37157442-EFBA7E30-1130-467F-9761-0CF0F53E166EQ37202761-9EB412FE-30F6-4DF6-8FCE-72663018FFA6Q37209929-F1519BEC-DEE0-4BFB-9C8B-8135F766E734Q37411805-BE6E46CC-28F6-419C-A4EC-2DE142988A7CQ37750106-2547D374-F797-4184-997F-932B785A10AFQ37875193-5FB0766D-D86C-4AE9-88FF-6C489B97B567Q37903590-0FB1D11B-2319-438B-BA19-DCD020993D0BQ37908155-4D961491-151D-4841-BC8F-7F42A1E41E68Q37937699-DDD5EF0D-EEF9-4ADE-8C1D-1DA9055DE1D1Q37978343-60784E86-5C5F-4F0C-B36F-DD16068D4DB7Q37986358-A6713672-3202-4998-BCF3-61069442F4DAQ38109235-C6621BC9-1E20-41C9-9D29-2EA34A9BFC8EQ38122674-D1ECFC42-E4EC-45A3-A0B6-7BF5D2C48D3BQ38182683-EBCE54C5-510C-421A-951B-A1A09DA4A2FB
P2860
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Activity and safety of bortezo ...... lticenter retrospective study.
@en
Activity and safety of bortezo ...... lticenter retrospective study.
@nl
type
label
Activity and safety of bortezo ...... lticenter retrospective study.
@en
Activity and safety of bortezo ...... lticenter retrospective study.
@nl
prefLabel
Activity and safety of bortezo ...... lticenter retrospective study.
@en
Activity and safety of bortezo ...... lticenter retrospective study.
@nl
P2093
P1433
P1476
Activity and safety of bortezo ...... lticenter retrospective study.
@en
P2093
Asher A Chanan-Khan
Jayesh Mehta
Jonathan L Kaufman
Joseph Tariman
Kena C Miller
Nikhil C Munshi
Robert Schlossman
Seema Singhal
P304
P356
10.1182/BLOOD-2006-09-046409
P407
P577
2006-11-30T00:00:00Z